(Neo)Adjuvant Treatment with or without Zoledronic Acid for Stage II or III Breast Cancer


(Neo)Adjuvant Treatment with or without Zoledronic Acid for Stage II or III Breast Cancer
Slides from a presentation at SABCS 2010, comments from an interview with Harold J Burstein, MD, PhD (12/22/10) and comments by Clifford Hudis, MD at an RTP satellite symposium during SABCS 2010 (12/11/10)

Coleman RE et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). San Antonio Breast Cancer Symposium 2010;Abstract S4-5.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.

Dr Hudis is Chief of the Solid Tumor Division’s Breast Cancer Medicine Service in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and is Professor of Medicine at Weill Cornell Medical College in New York, New York.